Search Results

• A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing

  A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing

• A 4-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 12 Years Old

  A 4-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 12 Years Old

• Project:EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study

  Project: EveryChild a Registry, Eligibility Screening, Biology and Outcome Study

• Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

• Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)

  AGCT1532 - Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

• Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

  Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

• Tipifarnib and Naxitamab for Relapsed/​Refractory Neuroblastoma

  Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

• Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  Phase I/II Study of Silmitasertib (CX-4945) in Combination With Chemotherapy in Children and Young Adults With Relapsed Refractory Solid Tumors

• LONG-TERM STUDY OF TRIPTORELIN IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY

  LONG-TERM STUDY OF TRIPTORELIN IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY